Literature DB >> 16943230

Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2.

Bojun Zhao1, Gill Smith, Jun Cai, Aihua Ma, Mike Boulton.   

Abstract

AIM: To determine vascular endothelial growth factor C (VEGF-C) expression in retinal endothelial cells, its antiapoptotic potential and its putative role in diabetic retinopathy.
METHOD: Cultured retinal endothelial cells and pericytes were exposed to tumour necrosis factor (TNF)alpha and VEGF-C expression determined by reverse transcriptase-polymerase chain reaction. Secreted VEGF-C protein levels in conditioned media from endothelial cells were examined by western blotting analysis. The ability of VEGF-C to prevent apoptosis induced by TNFalpha or hyperglycaemia in endothelial cells was assessed by flow cytometry. The expression of VEGF-C in diabetic retinopathy was studied by immunohistochemistry of retinal tissue. RESULT: VEGF-C was expressed by both vascular endothelial cells and pericytes. TNFalpha up regulated both VEGF-C and vascular endothelial growth factor receptor-2 (VEGFR)-2 expression in endothelial cells in a dose-dependent manner, but had no effect on VEGFR-3. Flow cytometry results showed that VEGF-C prevented endothelial cell apoptosis induced by TNFalpha and hyperglycaemia and that the antiapoptotic effect was mainly via VEGFR-2. In pericytes, the expression of VEGF-C mRNA remained stable on exogenous TNFalpha treatment. VEGF-C immunostaining was increased in retinal vessels in specimens with diabetes compared with retinal specimens from controls without diabetes.
CONCLUSION: In retinal endothelial cells, TNFalpha stimulates the expression of VEGF-C, which in turn protects endothelial cells from apoptosis induced by TNFalpha or hyperglycaemia via VEGFR-2 and thus helps sustain retinal neovascularisation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943230      PMCID: PMC1994741          DOI: 10.1136/bjo.2006.101543

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  41 in total

1.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Authors:  M Fràter-Schröder; W Risau; R Hallmann; P Gautschi; P Böhlen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

2.  Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha.

Authors:  S J Leibovich; P J Polverini; H M Shepard; D M Wiseman; V Shively; N Nuseir
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

3.  Growth of retinal capillary endothelia using pericyte conditioned medium.

Authors:  H C Wong; M Boulton; J Marshall; P Clark
Journal:  Invest Ophthalmol Vis Sci       Date:  1987-11       Impact factor: 4.799

4.  Expression of placenta growth factor is regulated by both VEGF and hyperglycaemia via VEGFR-2.

Authors:  Bojun Zhao; Jun Cai; Mike Boulton
Journal:  Microvasc Res       Date:  2004-11       Impact factor: 3.514

5.  Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis.

Authors:  H Kubo; T Fujiwara; L Jussila; H Hashi; M Ogawa; K Shimizu; M Awane; Y Sakai; A Takabayashi; K Alitalo; Y Yamaoka; S I Nishikawa
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

6.  Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha.

Authors:  F Bussolino; G Camussi; C Baglioni
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

7.  Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model.

Authors:  S Takeshita; L P Zheng; E Brogi; M Kearney; L Q Pu; S Bunting; N Ferrara; J F Symes; J M Isner
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

8.  Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells.

Authors:  K Okamura; Y Sato; T Matsuda; R Hamanaka; M Ono; K Kohno; M Kuwano
Journal:  J Biol Chem       Date:  1991-10-15       Impact factor: 5.157

9.  Dual role of tumor necrosis factor-alpha in angiogenesis.

Authors:  L F Fajardo; H H Kwan; J Kowalski; S D Prionas; A C Allison
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

10.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling.

Authors:  H Vlassara; M Brownlee; K R Manogue; C A Dinarello; A Pasagian
Journal:  Science       Date:  1988-06-10       Impact factor: 47.728

View more
  4 in total

1.  Endothelial cell Bcl-2 and lymph node metastasis in patients with oral squamous cell carcinoma.

Authors:  Sandra B C Tarquinio; Zhaocheng Zhang; Kathleen G Neiva; Peter J Polverini; Jacques E Nör
Journal:  J Oral Pathol Med       Date:  2011-09-21       Impact factor: 4.253

2.  Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach.

Authors:  Chiara Bianca Maria Platania; Rosa Maisto; Maria Consiglia Trotta; Michele D'Amico; Settimio Rossi; Carlo Gesualdo; Giovanbattista D'Amico; Cornel Balta; Hildegard Herman; Anca Hermenean; Franca Ferraraccio; Iacopo Panarese; Filippo Drago; Claudio Bucolo
Journal:  Br J Pharmacol       Date:  2019-05-09       Impact factor: 8.739

3.  Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR).

Authors:  Vidhya R Rao; Elizabeth Prescott; Namdev B Shelke; Ruchit Trivedi; Peter Thomas; Craig Struble; Tom Gadek; Charles A O'Neill; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-05       Impact factor: 4.799

4.  Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization.

Authors:  Alessandra Puddu; Roberta Sanguineti; Arianna Durante; Massimo Nicolò; Giorgio L Viviani
Journal:  Mol Vis       Date:  2012-10-11       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.